Kornimate/medical-research-clean huggingface dataset:
effect of quercetin in treatment of periodontitis

Conditions: Inflammation Gum

Summary: periodontitis is an immune-inflammatory disease affecting the supporting structures of the teeth. it is a disease of multifactorial etiology, with microbial, genetic, environmental and host factors involved, with the release of oxygen-free radicals by the inflammatory cells. quercetin, have shown potential antimicrobial activity, lowering of inflammatory markers, cholesterol reduction and inhibiting bone loss. however, this data has largely been obtained from in vitro and animal studies, but data from human studies are limited.

quercetin has been found to decrease the extracellular matrix degradation, promote wound healing when tested in gingival fibroblasts, and showed excellent antibacterial properties. it also possesses antioxidant effect which can be explored to restrict the inflammation in periodontitis. despite the beneficial effects of quercetin, its poor aqueous solubility and poor bioavailability result in limited absorption, so scientists have worked on improving the bioavailability of quercetin using various approaches, such as nanosuspension , self-nano emulsifying systems , microemulsion , solid lipid nanoparticles and cyclodextrin complexes. the combination of oils and emulsifiers enhances the absorption of quercetin. hence, nanoemulsion could be a suitable drug delivery vehicle for the loading of quercetin. nanoemulsions are more beneficial than microemulsions, as they have high kinetic stability and a smaller droplet size. therefore, the present study will investigate the efficacy of nanoemulgel of quercetin as adjunct to conventional therapy in treatment of periodontitis.

Eligibility criteria:
inclusion criteria: * inclusion criteria: * patients with periodontitis stage ( ⅰ \& ⅱ ). stage i have cal 1 to 2mm with no tooth loss and probing depth ≤4 mm. stage ii have cal 3 to 4mm with no tooth loss and probing depth ≤5 mm.. * patients who have teeth with both mesial and distal neighboring teeth . * patient with more than 20 natural teeth . * patient free from any systemic disease that may effect the periodontal status according to the criteria of cornell medical index and its modification. exclusion criteria: * long-term therapy with medications within a month prior to enrollment that could affect periodontal status or healing. * pregnant woman and lactating mothers . * patients with a history of traumatic occlusion. * teeth with both endo-perio lesion . * patients with previous periodontal treatment including scaling and root planing and periodontal surgery in the last 3 and 6 months, respectively .

Keywords: periodontitis inflammation quarcetin nanoemulgel
transgastric peritoneoscopy and appendectomy

Conditions: Abdominal Pain

Summary: this study is a feasibility study. patients with acute abdominal pain who are planning to undergo a diagnostic laparoscopy are asked to participate in the study. the aim of the study is to evaluate if transgastric peritoneoscopy is feasible.


Eligibility criteria:
inclusion criteria: * patient with acute abdominal pain exclusion criteria: * patient under 18 * patient who cannot understand information in swedish * patients previously operated in upper part of the abdomen

Keywords: notes transgastric appendectomy safety feasibility
culturally-informed counseling in latinas at high risk for hereditary breast or ovarian cancer

Conditions: No Evidence of Disease; BRCA1 Syndrome; BRCA2 Syndrome; Hereditary Female Breast Carcinoma; Hereditary Ovarian Carcinoma

Summary: this pilot clinical trial studies a culturally-informed counseling intervention in latinas at high risk for hereditary breast or ovarian cancer. a culturally-informed counseling intervention may be an effective method to help people learn more about their cancer risk.

primary objectives: i. to conduct a randomized trial of a culturally-informed pre-genetic cancer risk assessment (gcra) telephone intervention. ii. to evaluate the effect of the pre-gcra intervention versus a time and attention control versus standard scheduling procedure alone (usual care) on levels of anxiety, perceived personal control and cancer genetics knowledge. iii. to explore patients' experiences with the pre-gcra intervention through post-intervention telephone interviews. secondary objectives: i. to explore patients' perceived barriers to gcra through no-show telephone interviews. outline: patients are randomized to 1 of 3 treatment arms. arm i: patients receive a culturally-informed adapted motivational interviewing telephone call. arm ii: patients participate in a controlled condition comprising a health habits intervention group. arm iii: patients receive usual care comprising a standard scheduling phone call and proceed with normal gcra process. all patients are mailed standard new patient packets containing questionnaires on demographics and personal health history, and a family history form. all patients then undergo genetic cancer risk assessment.

Eligibility criteria:
inclusion criteria: * individuals who have a personal history of hereditary breast or ovarian cancer; a subset of 60 women without a personal history of hereditary or ovarian cancer will be included in an exploratory subset analysis * meet nccn criteria for consideration of genetic testing for hereditary breast cancer * willing to sign consent * pregnant women and women of child-bearing potential are eligible for participation in this study * women who report themselves to be of latino or hispanic ethnic background (defined as spanish, mexican, central or south american, cuban, puerto rican, dominican, or other hispanic origin) * women who are under- or uninsured and come from low-income communities * ability to understand english or spanish exclusion criteria: * previous participation in gcra
the effects of attentional focus on arm training in stroke

Conditions: Stroke

Summary: this study compares the effects of an internal versus an external focus of attention on motor training of the affected arm for individuals with stroke. participants were randomly assigned to either the internal or external focus treatment groups and received 12 sessions of arm training.

participants were randomized to one of two treatment groups and received upper arm reaching training on the inmotion 2 shoulder robot (12 hourly sessions over four weeks). the external focus group received instructions specifically to pay attention to the task goal--hitting targets on the video game, while the internal focus group was instructed to pay attention to the movement of their arm motions (video game monitor was turned off). both groups practiced the same arm reaching pattern and were matched for level of arm impairment and training dosage.

Eligibility criteria:
inclusion criteria: * diagnosis of stroke \> 6 months * moderate to severe arm impairment * intact visual scanning and spatial orientation of the affected arm * functional cognitive status * medically stable exclusion criteria: * concurrent occupational or physical therapy for the arm * joint contractures at the wrist, forearm, elbow, or shoulder * moderate to severe spasticity at the elbow or shoulder * presence of other neurological conditions * botulinum toxin injection in the affected arm \< 3 months prior * score of 0/5 on manual muscle test at the elbow or shoulder

Keywords: attentional focus upper extremity hemiparesis stroke
kidney protection using the renalguard® system in cardiac surgery

Conditions: Acute Renal Injury

Summary: this is a prospective randomised control trial 1:1 in patients at risk of developing acute kidney injury after cardiac surgery comparing the renalguard® system to current medical treatment. 110 patients will be recruited for each group. the aim of the study is to assess whether the renalguard® system reduces acute kidney injury (aki) after cardiac surgery as compared to current practice.

patients undergoing elective or in-house urgent cardiac surgery will be approached for the kidney study if they fulfil the inclusion criteria. upon consent pre-operative blood tests will be as per the usual practice. moreover, 2ml of the serum will be stored for ngal analysis. following the consenting process, patients will be randomised (envelop- based) into either having the renalguard® system (study group) or current medical management (control group). study group: patients in the study group will have the renalguard® system started in anaesthetic room once the peripheral line and arterial lines are sited. the renalguard® system will continue to run throughout the cardiac procedure in the operating room and up to 6 hours post-op after the patient has been transferred to the unit. patients will be managed at a zero balance i.e. volume of the urine output will be matched to the volume of hartmann's fluid infusion. forced diuresis is then initiated. control group: patients in the control group will be managed as per current medical practice which will include no forced diuresis in operating room and the use of inotropes for maintenance of mean arterial pressure and intravenous furosemide for diuresis. an additional blood test (ngal) at six hours post-op will be taken and would require 2mls of blood. the ngal specimens will be dealt with by the biochemistry lab (centrifuged \& stored) so that the specimens can be analysed in batches. patients kidney function (u\&es) will be tested at the time of post-operatively as per usual practice (day1, pre-discharge and as clinically indicated) and at the post-operative surgical out-patient visit. pre-operative, intra-operative and post-operative data will be collected for each patient group.

Eligibility criteria:
inclusion criteria: 1. patients undergoing surgery (elective or in-house urgent) 2. patient 18 years old and over 3. patient able to give written consent 4. patient at risk of developing aki after cardiac surgery (at least one factor) 1. diabetics (iddm or niddm) with normal kidney function pre-op 2. patients with egfr 20-60 3. patients undergoing combined cardiac procedures when the cpb time is likely to exceed 120 minutes 4. patients with hb of 12.5 g/dl or below 5. logistic euroscore of 5 and above 5. patient not involved with another study exclusion criteria: 1. emergency surgery 2. patient unable to give written consent 3. patient already dialysis dependent or egfr \<20 4. patient partaking in another study 5. pregnant patients
study in airway physiology in children seretide diskus ® inhlaer and flixotide® inhaler are trademarks of gsk group of companies.

Conditions: Asthma

Summary: comparison of two asthma treatments by lung function measures.


Eligibility criteria:
inclusion criteria: * currently receiving 200-800mcg/day beclomethasone dipropionate. * sraw value of 1.3 kpa's. exclusion criteria: * 3 or more courses of oral steroids in last 12 months.

Keywords: asthma inhaled corticosteroids
goal attainment scaling in upper limb spasticity treatment

Conditions: Ischemic Stroke; Hemorrhagic Stroke

Summary: patients after stroke with upper limb spasticity treated with botulinum toxin-a (btx-a) will be included in this two-part study. in the first part, goal attainment scaling and comprehensive assessment of motor functioning will be performed before btx-a application and after two weeks. in the second part, the patients will be randomised into a test group performing prescribed regular exercise for two weeks and a control group exercising at their own discretion during the same period, whereby the patients' health-related quality of life will be assessed at the beginning and end of the two-week period.

goal setting will be performed by the patient together with the physician according to the smart principle (specific, measureable, achievable, realistic, time bound). the goals will be classified according to the international classification of functioning, disability and health. goal attainment will be assessed using the goal attainment scale - light. comprehensive assessment of motor functioning will address range of motion, spasticity, pain, degree of motor disability and degree of dependence in daily activities. the prescribed exercises for the test group will be passive or active, depending on spasticity of the impaired upper limb. both groups will keep an exercise diary during the second part of the study.

Eligibility criteria:
inclusion criteria: * patient's or caregiver's approval * ischemic or hemorrhagic stroke diagnosed using head ct/mri * at least one upper limb muscle spasticity (mas ≥ 3) * candidate for btx-a treatment or already given btx-a in the past * patient's or caregiver's capability for goal attainment protocol cooperation (mini mental examination ≥ 24 points) exclusion criteria: * aphasic patients without caregiver's presence * other neurological or musculoskeletal diseases that could affect the treatment outcome

Keywords: rehabilitation spasticity botulinum toxin a goal setting spasticity-related quality of life
safety, efficacy and dose-response study of bms-986001 in subjects with hiv-1 infection who are treatment-naive

Conditions: HIV-1 Infection

Summary: the purpose of this study is to identify at least one dose of bms-986001 which is safe, well tolerated, and efficacious when combined with efavirenz (efv) + lamivudine (3tc) for treatment-naive human immunodeficiency virus 1 (hiv-1) infected subjects

double blind through week 24. partially blind (to subjects, caregivers, investigators) through week 48.

Eligibility criteria:
inclusion criteria: * at least 18 years of age, (or minimum age as determined by local regulatory or as legal requirements dictate, whichever is higher) * plasma hiv-1 rna \> 5000 copies/ml * antiretroviral treatment-naive; defined as no current or previous exposure to \> 1 week of an antiretroviral drug * cd4+ t-cell count \> 200 cells/mm3 exclusion criteria: * resistance to any of the study medications \[tenofovir disoproxil fumarate(tdf), efavirenz (efv), lamivudine (3tc)\] or to hiv protease inhibitors (pis) * contraindications to any of the study drugs
medication strategies for treating aggressive behavior in youth with attention deficit hyperactivity disorder

Conditions: Attention Deficit Disorder With Hyperactivity; Conduct Disorder; Oppositional Defiant Disorder

Summary: this study will assess whether adding a mood stabilizer, divalproex sodium, to stimulant treatment is more effective than stimulant treatment alone in reducing aggressive behavior among children with attention deficit hyperactivity disorder (adhd).

adhd is one of the most common childhood mental disorders. it often causes impaired functioning in multiple areas, including home, school, and peer relationships. additionally, children with adhd often develop aggressive behavior, which is not usually adequately suppressed by standard stimulant treatments for adhd. in order to address this problem, many physicians prescribe multiple medications at once. there is no clinical evidence, however, proving that this method is safe and effective. this study will assess whether adding a mood stabilizer, divalproex sodium, to stimulant treatment is more effective than stimulant treatment alone in reducing aggressive behavior among children with adhd. participants in this double blind study will first receive open label stimulant treatment for adhd and a comorbid disruptive behavior disorder. participants whose aggressive behavior subsides with stimulant treatment alone will not proceed into the next phase of the study. participants whose adhd symptoms lessen from the treatment but whose aggressive behavior persists will be randomly assigned to receive either divalproex sodium or placebo in addition to their stimulant treatment for 8 weeks. study visits will be held weekly for 11 to 16 weeks. at these visits, aggression levels and medication side effects will be assessed. families will also meet with the researchers to discuss the child's progress, and attend behavioral counseling with a therapist. participants who did not continue into the second phase of the study will be asked to return to the study site for a follow-up visit 8 weeks following the end of the first phase.

Eligibility criteria:
inclusion criteria: * diagnosis of adhd * diagnosis of opposition defiant disorder or conduct disorder * score that exceeds the study threshhold on the standardized scale of aggressive behavior exclusion criteria: * current psychosis * current major depression * current pervasive developmental disorder * current obsessive compulsive disorder * any other anxiety disorder as primary diagnosis * mental retardation

Keywords: adhd odd conduct disorder cd
a study of carmustine with and without ethanol in subjects with lymphoma

Conditions: Lymphoma; Non-Hodgkin Lymphoma; Hodgkin Lymphoma

Summary: a phase 2 multicenter study of vi-0609 vs bicnu in the beam high-intensity conditioning regimen for ahct in subjects with lymphomas.


Eligibility criteria:
inclusion criteria: * male and female adults ≥ 18 years of age with a life expectancy ≥ 6 months; * karnofsky performance status ≥ 70%; * histologically confirmed hodgkin lymphoma or non-hodgkin lymphoma; * candidate for ahct consolidation therapy as assessed by their treating physician; * achieved a complete or partial response; * completed collection of at least 2.0 x 10\^6 cd34 cells/kg of autologous hematopoietic progenitor cells (hpcs) by apheresis; * recovery from non-hematologic toxicities of salvage cytoreductive chemotherapy to ≤ grade 2; * clinical laboratory and organ function criteria meeting study ranges/limits lvef ≥ 50%; fev1 \> 65% of predicted measurement, dlco ≥ 50% of predicted; * seronegative for hiv ag/ab combo, hcv, active hbv, and syphilis exclusion criteria: * prior high-dose chemotherapy with autologous stem cell transplant, or prior allogeneic transplantation; * significant prior external beam dose-limiting radiation to a critical organ based on review of the prior radiation treatment records; * use of any other investigational medication or device, or concurrent biological, chemotherapy, or radiation therapy; * myelodysplasia or any active malignancy other than hl or nhl, or \< 5 years remission from any other prior malignancy; * any cytogenetic abnormality in the bone marrow that is known to be associated with or predictive of myelodysplasia; * persistent marrow involvement (\>10%) with hl or nhl after salvage cytoreductive therapy and before stem cell mobilization; * not having sufficient bone marrow harvest to reach adequate cell dose for transplant; * active hepatitis b or c viral infection or hbsag positive; * positive hiv antibody;

Keywords: lymphoma ahct bicnu carmustine
dermacyd silver frutal (lactic acid) - compatibility.

Conditions: Hygiene

Summary: primary objective: to demonstrate the absence of irritation potential (primary dermic irritability and cumulated dermic irritability) and allergy (sensibilization) of the product dermacyd silver frutal.


Eligibility criteria:
inclusion criteria: * phototype skin i,ii, iii e iv * integral skin test in the region * willingness in following the study procedures and to be present in the clinic at the days and scheduled time for medical evaluations and for application of occlusion exclusion criteria: * lactation or pregnancy * use of antiinflammatory 30 days and/or immunossupression drugs for until 3 months before volunteers selection * diseases which can cause immunosuppresion, such as diabetes, hiv * personal history of atopy * history of sensitivity or irritation for topic products * cutaneous active disease (local and/or general) which can modify the study results * use of new drugs and/or cosmetics during the study * cutaneous reaction * previous participation in studies using the same product in test * volunteer which has immunodeficiency congenital or acquired * relevant history or confirmation of alcohol or other drugs abuse * intolerance detected or suspected for some component of the sample tested * medecin or sponsor employees or their close family. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
heparin solution and intem/heptem analysis

Conditions: Brain Tumor; Spinal Stenosis; Cerebral Artery Anuerysm

Summary: heparinized solution has been used for maintenance of arterial catheter during perioperative period. although the infused dose of heparin is very low, the investigators examine whether the heparin effect is remained or not in blood using rotational thromboelastometry (rotem) analysis.


Eligibility criteria:
inclusion criteria: * patients requiring continuous invasive arterial pressure monitoring during operation for anesthetic management. exclusion criteria: * heparin hypersensitivity * hematologic disease * anticoagulant medication
clinical evaluation of genetron lung cancer panel in non-small cell lung cancer patients

Conditions: Non-Small Cell Lung Cancer

Summary: the purpose of this trail is to evaluate the performance of genetron lung cancer panel in non-small cell lung cancer patients using semiconductor sequencing method.

this trial follows the principle of synchronous blinding. the enrolled cases are coded, and the enrolled samples are detected with genetron lung cancer panel and comparison methods. the detection results are compared, and the samples that are inconsistent with the detection results of similar products on the market are reviewed by the the sanger sequencing method, when the site detection results compared with sanger sequencing method are inconsistent, sanger's detection results are recognized. the safety and effectiveness of this panel are confirmed and evaluated. meanwhile, the accuracy of this panel for the following drug companion diagnostic tests: egfr gene 19 exon deletion and l858r point mutation in gefitinib tablets, erlotinib hydrochloride and icotinib hydrochloride tablets, t790m point mutation in methanesulfonate acid osimertinib tablets, alk gene fusion in crizotinib capsules. the results were determined independently according to the cutoff values or interpretation requirements provided by each method, and relevant statistics were used to evaluate clinical application performance of genetron lung cancer panel.

Eligibility criteria:
inclusion criteria: 1. cancer samclinically diagnosed as non-small cell lung samples (mainly lung adenocarcinoma and some lung squamous cell carcinoma, adenosquamous carcinoma, large cell carcinoma, etc.), and a small number of other cancer types are enrolled as interference samples. 2. collect some samples of relevant medical information before and after the use of targeted drugs. this part of the samples should have relevant previous molecular diagnosis results. 3. able to provide samples in time according to the requirements of the plan: samples for dna/rna extraction: 10 pieces of 10 µm thickness for each sample or 10 pieces of paraffin rolls. samples for fish experiment: 5 slices of 3-4µm thickness. 4. the pathological examination conforms to the types of tissue samples listed in the above table. the he staining results show that the tumor content is not less than 50%, and the paraffin slice damage should be avoided. 5. the sample should have corresponding basic clinical information, including: patient visiting number/medical record number/specimen number, age, gender, pathological diagnosis result, molecular diagnosis result (if any). exclusion criteria: * those who do not meet any of the above conditions are excluded. reason: the included non-small cell lung adenocarcinoma samples and normal samples should have statistical significance, and the conclusions obtained should be scientific and valid. the selection of subjects for this study, while excluding research-related influencing factors, has no adverse effect on the health of the subjects.